Improved asthma outcomes for dupilumab plus medium-dose inhaled corticosteroids versus placebo plus high-dose inhaled corticosteroids - PubMed
4 hours ago
- #asthma treatment
- #dupilumab
- #inhaled corticosteroids
- Dupilumab combined with medium-dose inhaled corticosteroids (ICS) showed improved asthma outcomes compared to placebo with high-dose ICS.
- The analysis involved patients with baseline eosinophils ≥150 cells/µL or fractional exhaled nitric oxide ≥20 ppb and at least one exacerbation in the prior year.
- Dupilumab plus medium-dose ICS reduced severe exacerbations by 70% versus placebo plus high-dose ICS, with statistical significance (P < 0.0001).
- At week 52, pre-bronchodilator FEV1 improved by 0.22 L, and the odds ratio for achieving asthma control increased to 2.26 with dupilumab plus medium-dose ICS versus placebo plus high-dose ICS.
- These post hoc findings suggest potential benefits of adding dupilumab over escalating ICS dose, warranting further direct comparison studies.